高级检索

司美格鲁肽生物类似药JY29-2治疗2型糖尿病的有效性与安全性:一项多中心、随机、平行对照Ⅲ期临床试验

Efficacy and safety of a semaglutide biosimilar JY29-2 in patients with type 2 diabetes mellitus: a multicenter, randomized, parallel-controlled phase Ⅲ clinical trial

  • 摘要:
    目的 比较司美格鲁肽生物类似药JY29-2与参照药司美格鲁肽注射液(诺和泰)治疗2型糖尿病(type 2 diabetes mellitus, T2DM)的有效性和安全性。
    方法 本研究为多中心、随机、开放、平行对照的Ⅲ期临床试验。纳入2022年7月1日至2023年10月31日中国34家临床研究中心的T2DM患者,按1∶1的比例随机分为JY29-2组与诺和泰组,两组均联合二甲双胍治疗32周。主要终点指标为治疗32周后糖化血红蛋白(glycated hemoglobin A1C, HbA1C)较基线的变化值。采用协方差分析(analysis of covariance, ANCOVA)模型,对主要疗效指标进行等效性检验,等效性界值设定为±0.4%。次要终点指标包括空腹血糖、体质量、脉搏、血压、血脂等较基线的变化值,同时评估治疗期间出现的不良事件、免疫原性和药代动力学(pharmacokinetics, PK)特征。
    结果 共纳入476例患者,JY29-2组和诺和泰组各238例。治疗32周后,JY29-2组和诺和泰组HbA1C较基线变化分别为−1.79%(95%CI −1.94%~−1.65%)与−1.70%(95%CI −1.83%~−1.56%),两组差异无统计学意义。JY29-2组与诺和泰组HbA1C较基线变化的最小二乘均数分别为−1.78%(95%CI −1.89%~−1.67%)与−1.69%(95%CI −1.80%~−1.58%),两组最小二乘均数差为−0.08%(95%CI −0.24%~0.07%),在预设的等效性界值范围(−0.4%~0.4%)内。两组患者的次要终点指标、不良事件发生率差异均无统计学意义。两组药物的PK具有相似性,抗药抗体(anti-drug antibody, ADA)结果均为阴性。
    结论 在中国T2DM患者中,司美格鲁肽生物类似药JY29-2的有效性和安全性与参照药诺和泰相当,JY29-2是治疗T2DM的一种有效药物。

     

    Abstract:
    Objective To compare the efficacy and safety of the semaglutide biosimilar JY29-2 with originator semaglutide (Ozempic) in patients with type 2 diabetes mellitus (T2DM).
    Methods This was a multicenter, randomized, open-label, parallel-group, phase 3 trial. From July 1, 2022 to October 31, 2023, patients with T2DM enrolled at 34 clinical centers in China were randomized in a 1:1 ratio to receive JY29-2 or Ozempic for 32 weeks, both in combination with metformin. The primary endpoint was the change from baseline in glycosylated hemoglobin A1C (HbA1C) at week 32. An analysis of covariance (ANCOVA) model was used to perform an equivalence test on the primary efficacy endpoint, with the equivalence margin set at ±0.4%. The secondary endpoints included changes from baseline in fasting blood glucose, body weight, pulse, blood pressure and lipid profile. Treatment emergent adverse events (TEAEs), immunogenicity and pharmacokinetics (PK) were also evaluated.
    Results A total of 476 patients were included, with 238 cases in each group. At week 32, the mean change from baseline in HbA1C for the JY29-2 group and Ozempic group were −1.79% (95%CI −1.94% – −1.65%) and −1.70% (95%CI −1.83% – −1.56%), respectively. No statistical difference was observed between the two groups. The least squares mean changes from baseline in HbA1C were −1.78% (95%CI −1.89% – −1.67%) in the JY29-2 group and −1.69% (95%CI −1.80% – −1.58%) in the Ozempic group. The difference in the least squares mean between the two groups was −0.08% (95%CI −0.24% – 0.07%), which fell within the pre-specified equivalence margin of −0.4% – 0.4%. No statistical differences were observed between JY29-2 group and Ozempic group for the secondary endpoints and TEAEs. The PK parameters were similar between the two groups, and anti-drug antibody (ADA) results were negative in both groups.
    Conclusions The semaglutide biosimilar JY29-2 demonstrates similar efficacy and safety to Ozempic in patients with T2DM, supporting its use as an effective treatment option for T2DM.

     

/

返回文章
返回